Clinical Trial Update: Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial [Phase 3]

View source ↗

Summary

A Phase 3 registration trial evaluating Taxotere (docetaxel) for squamous cell carcinoma of the head and neck has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: Sanofi | Conditions: Head and Neck Neoplasms | Phase 3 | Status: COMPLETED